Business Context and Reporting Period
This Form 8-K is filed by Silexion Therapeutics Corp on August 3, 2026, reporting events that occurred on August 1, 2026. The Company is incorporated in the Cayman Islands and its ordinary shares and warrants trade on The Nasdaq Stock Market under the symbols SLXN and SLXNW, respectively. The filing addresses corporate governance changes regarding the Board of Directors and the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Board Resignation: Professor Amnon Peled resigned from the Board of Directors and all committees, including the Audit Committee, effective August 1, 2026. The resignation was for personal reasons and did not involve any disagreement with the Company regarding operations, policies, or practices.
- Board Appointment: Effective August 1, 2026, Mr. Avner Lushi, an existing independent Board member since August 2024, was appointed to the Audit Committee to fill the vacancy.
- Committee Composition: The Audit Committee now consists of three independent members: Dror J. Abramov (Chair and financial expert), Ruth Alon, and Avner Lushi.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business strategy. The primary risk addressed is regulatory compliance; the appointment of Mr. Lushi restored full compliance with Nasdaq Listing Rule 5605(c)(2)(A), which mandates a minimum of three independent Audit Committee members. The Company achieved this compliance without utilizing the cure period provided under Nasdaq Listing Rule 5605(c)(4)(B).
Investor Verification Checklist
- Verify the independence status of the new Audit Committee members (Dror J. Abramov, Ruth Alon, and Avner Lushi) under Nasdaq rules.
- Confirm that the resignation of Professor Peled was indeed for personal reasons and not related to any undisclosed disagreements.
- Review Mr. Lushi's background as Managing Partner and CEO of the Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF) for potential conflicts of interest.
- Check subsequent filings for any further changes to the Board composition or Audit Committee structure.